Share Name Share Symbol Market Type Share ISIN Share Description
Widecells Group Plc LSE:WDC London Ordinary Share GB00BD060S65 ORD GBP0.0025
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.00% 0.285 0.00 01:00:00
Bid Price Offer Price High Price Low Price Open Price
0.28 0.29 0.00 0.00 0.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.05 -2.81 -5.00 4.0
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 0.00 GBX

Widecells (WDC) Latest News

More Widecells News
Widecells Takeover Rumours

Widecells (WDC) Share Charts

1 Year Widecells Chart

1 Year Widecells Chart

1 Month Widecells Chart

1 Month Widecells Chart

Intraday Widecells Chart

Intraday Widecells Chart

Widecells (WDC) Discussions and Chat

Widecells (WDC) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Widecells trades in real-time

Widecells (WDC) Top Chat Posts

DateSubject
17/7/2019
09:20
Widecells Daily Update: Widecells Group Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker WDC. The last closing price for Widecells was 0.29p.
Widecells Group Plc has a 4 week average price of 0.25p and a 12 week average price of 0.25p.
The 1 year high share price is 3.50p while the 1 year low share price is currently 0.15p.
There are currently 1,399,302,698 shares in issue and the average daily traded volume is 59,583,142 shares. The market capitalisation of Widecells Group Plc is £3,988,012.69.
09/7/2019
11:11
ihavenoclue: Rule Number 1 : Don't get emotional about investing. 1blue, I have put you down as a fail on that one. Now let's have a look at funding, DS gets funding from EHGOS for WDC to clear up legacy issues that was supposed to put a floor on the share price of 0.4p. in fact the share price dropped down to 0.3p so the deal occurred an extra 25% loss to the shareholder. Then DS again goes to EHGOS, ignoring better offers, to fund drilling for AAOG. How is that in the best interests of the shareholders there as LB28 already mentioned. So why does DS go to EHGOS if they have already damaged a share he has dealings with ? He MUST be getting some kind of 'commission' yet to suggest that I get called a cretin. 1blue, please explain, taking out what the companies do as that has NOTHING to do with what I mentioned, how DS doing a deal with EHGOS is in the best interests of the shareholder ? You say my avatar is correct but it seems more and more like you should own it. Also I am pretty sure you will be proved wrong before the week is out so I will be sure to mention it when it happens. Cheer up and take the emotion out of it, there's a good chap. Best Regards IHNC P.S. Don't threaten people online as you have NO idea who you are talking to :)
11/6/2019
18:44
pwhite73: livup967 I'm glad you mentioned BIDS because I have compared them to Iconic Labs. BIDS have a mcap of £86m which is where I think Iconic Labs should be. They haven't really got less shares than you either. Their share price is 35p yours is 0.35p. If you were to consolidate 100 - 1 and your share price was 35p you would only have 11.9mill shares. What BIDS hasn't got is a millstone round its neck called Widecells. That is why its market cap has ballooned along with its share price. The sooner the EGM is called and Widecells is got rid of the better.
09/6/2019
11:26
pwhite73: 74tom The EHGOS deal with warrants and prospectus was agreed and published in September 2018. The February 2019 Prospectus was just a rehash of it. In September 2018 the share price was 2.2p so the warrant exercise price of 2.46p was nothing out of the ordinary. However since then company has all but gone bust and the share price has crashed to what it is today. The reason why the old board was kicked out by the shareholders was because they set a conversion price of 0.25p when at the time the price was 2.2p. A 90% discount FFS. Not only that the old board agreed that they would lend their shares to EHGOS for shorting!!!. So you can see the WDC shareholders were completely shafted and the old board paid the price. Enter DS and Co.
09/6/2019
10:20
74tom: Haha, there are not 378m warrants at 2.46p! “The second series of Warrants (Warrants B) the Company will be required under the terms of the Financing Agreement to issue on the drawdown of each Subsequent Tranche (including the Second Tranche). Each issuance of Warrants B will be made on the drawdown of a Subsequent Tranche, and will grant to the Investor the right to subscribe for Warrant Shares with an aggregate subscription value of 20% of the nominal amount of the relevant Tranche at an exercise price (the Warrant B Exercise Price) of 120% of the lowest closing VWAP of the 15 trading days immediately preceding the request to issue the relevant Tranche.” Why the hell would a company subscribe for warrants that are 10x the share conversion price? They are 1 for 1 warrants in theory, but can be exercised higher if the share price increases. Also, that text you quoted re Alpha Blue Ocean isn’t in page 13 of this prospectus; hxxp://widecellsgroup.com/docs/WideCellsProspectusfeb2019.pdf Where have you got that from? Alpha Blue Ocean isn’t even mentioned in that document... If they wait until the share price reaches 2.46p before exercising the warrants then they will only receive 16.46m shares.
06/6/2019
17:15
pwhite73: EHGOS CONVERSIONS There is something else I think you all need to be made aware of. Under the minimum floor price EHGOS would convert at 0.40p and if the share price was lower at the time of the conversion WDC would make up the difference at the next conversion. At the last conversion the price was 0.36p therefore WDC need to make up the difference of 0.04p at the next conversion. The problem is this, the share price has fallen further so EHGOS are effectively selling at a loss. They are selling shares at 0.30p when converting at 0.40p. WDC will make up the difference from 0.36p to 0.40p but who is compensating EHGOS from 0.30p to 0.36p. Had EHGOS not entered into the minimum floor price agreement they would today be selling 0.25p shares at 0.30p. Between 0.25p and 0.36p is 0.11p. EHGOS are not going to take a hit of 45% on their conversion shares. Expect more conversion shares over and above what is in the Prospectus BIG TIME.
03/5/2019
08:33
datait: LSE:WDC Widecells Share News (WDC) 1 Following WDC BuySell Share Name Share Symbol Market Type Share ISIN Share Description Widecells Group LSE:WDC London Ordinary Share GB00BD060S65 ORD GBP0.0025 Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade -0.01p -2.94% 0.33p 0.32p 0.34p 0.34p 0.32p 0.34p 25,515,890 13:23:45 Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m) Health Care Equipment & Services 0.1 -2.8 -5.0 - 2.59 Print Alert WideCells Group PLC Financing Agreement 01/05/2019 4:00pm UK Regulatory (RNS & others) Widecells (LSE:WDC) Intraday Stock Chart Today : Wednesday 1 May 2019 Click Here for more Widecells Charts. TIDMWDC RNS Number : 7972X WideCells Group PLC 01 May 2019 1 May 2019 WideCells Group PLC ("WideCells" or the "Company") Financing Agreement WideCells announces that further to the Financing Agreement, announced on 27 September 2018, with European High Growth Opportunities Securitization Fund ("HGOSF"), it has today signed a deed of variation in which the two parties have agreed to set a minimum conversion price for the Bonds. The conversion price (per Share) for the Bonds is now the greater of: I. GBP0.004 (the "Minimum Conversion Price"), or II. 90% of the lowest closing volume-weighted average price of Ordinary Shares in the 15 trading days prior to conversion (the "Theoretical Conversion Price"). To the extent that the Theoretical Conversion Price is below the Minimum Conversion Price the shortfall in the amount converted will be settled at the time of the next tranche. Executive Chairman, David Sefton, said: "HGOSF has been highly supportive of the new strategy, and by providing capital, has been instrumental in our ability to restructure and pay off the outstanding legacy debts in WideCells, to the benefit of all stakeholders. We are very grateful for this support. HGOSF has also been open to discussions on restructuring the facility and this first part provides that, in essence, HGOSF cannot convert at a price below 0.4p, therefore providing a floor on the price. Furthermore, with its support we will look to increase this floor in the future, once the new business becomes more established. "With the first part of the restructuring complete, we are also discussing additional amendments to the financing structure and relationship that will reflect both HGOSF's long-term strategic support for the Company, and seek to further align the interests of all stakeholders. "On an operational level, we are very keen to update investors on the progress of the new business since the Iconic Labs team joined and intend to do so as soon as we have resolved certain unforeseen legacy issues. With the support of HGOSF and the new team, these issues are very close to being resolved, so we anticipate a full operational and business update in the near future."
28/4/2019
14:47
timw3: DS in the RNS of 25th April appears to have signalled that he no longer needs to acquire any conversion shares to attain control of the company. In addition that suggests he doesn't expect the issue of more conversions shares that will undermine his existing position. Further the apart from the initial cheap conversion shares which were at a set price, all future conversion shares (if there were to be any) would be issued at a price which reflects the actual share price of the company - as the monetary sums are fixed, a higher share price means fewer shares to be issued for the fixed sum, which in turn boosts the share price, thus resulting in a virtuous circle. Further whilst EHGOSF would be guaranteed a nice return on the cheap fixed price shares, any future shares to be issued would carry a much higher risk for EHGOSF , thus rendering their issue less likely. All signs point to no more conversion shares. Further EHGOSF, given that they have unloaded around 22% in the last 5 weeks and given they only had around 6% on Friday AM, and the volume that day (350M or 42% of the shares in issue) they could well now be down to zero. Thus the cheap flow of shares that restrained the share price at around .003p have now ceased. Clearly parties have been taking positions, quite a few TR1's to come next week, I think, and Mr Aftab with 5.81% is interesting. He only bought after DS signalled no more conversion shares. Is he in for a quick turn or to acquire the legacy Widecells buisness on favourable terms. If the latter has he left it too late to acquire a decent holding, given that the conversions share tap has now been turned off? At £3M WDC is barely valued at not much more than the costs of listing on the main market. Now there are no more cheap shares about, the Widecells business in play (it still has some valuable assets, licences etc), Mr Aftab wanting in (and possibly leaving it a bit late to build another decent stake so as to improve his negotiating position) there could be fireworks share pricewise next week. I think it is a case of "standby for action!"
27/4/2019
01:25
timw3: skittish Posts: 314 Opinion: Strong Buy Price: 0.435 RE: How highFri 22:31Surely the most important point is that Nuuco and DS no longer have any requirement for the £585,000 option in order to obtain effective control of the company, hence they have let it lapse. So that means that DS has sufficient support from existing shareholders (declared or not) to achieve his objectives of directional and name change for the company. The massive issue of new cheap shares has diluted previous holders and effectively rendered them powerless in voting terms. EHGOSF have done a quick turn on most of their cheap shares, which were issued at a set price. As the share price climbs, as appears likely, then new shares, if issued at all would be issued at a progressively higher price, and in far fewer numbers, in accordance with the formula referred to in the prospectus, rendering their issue much less attractive to EHGOSF, or DS if he had extended his option. The lapse of the option suggests to me that DS considers it unlikely that further shares will be issued under the financing arrangement, and thus his existing position and those of his supporters will not be under threat. It can be no coincidence that Mr Ahmed chose to buy 5% of the company on the same day DS elected to allow his option to lapse. Clearly he also believes that DS has signalled further dilution is unlikely, particularly as he sold his entire 15% holding in February shortly after DS took over. Presumably he had intended to influence the future direction of the company with that 15%, prior to it becoming a media focused company. Free of being diluted again he is back in with 5%, and possibly much more after today. To what end? Owning a sizeable chunk of WDC stock could be useful if he were interested in buying the legacy Widecells business, operating both as a cheap down payment and also to influence the outcome of negotiations. As the market cap remains at only £3.4M he could build up a sizeable stake cheaply and chip in with a bit of cash for the remainder of the Widecells part of the business. As for DS he will control the legal and financial side of the media business, whilst allowing the media guys (almost) free reign. It was their legal and financial incompetence which eventually sunk Unilad. With the "grown up" stuff taken out of their hands they could build a successful business. £3.4M for a media business with the Widecells business hived off to Mr Ahmed. Cheap. With enough shares now in his supporters hands and effective control DS can now tidy up the outstanding legal issues and move forward. The share price will, next week, respond accordingly.
16/3/2019
08:41
texas ranger: If you guys can correlate the number of shares vs/ mcap vs share price There is a strong correlation (inverse) Essentially the share price has declined substantially since issuance of shares. Meaning dilution 175% more shares in issue shows approximately about a -65% share price devaluation so far. This is in reference to 1.2p when the news came Just check out the chart. shares issue going up rapidly exponential is inversely correlated with s.p, and hence the share price will be drifting in a logarithmic decline, slow and painful new cheaper shares is coming on the market every day, meaning the ones who at 0.5p, 0.6p will have difficult to break even. Now it's anticipated that about 700m or 800m shares going to be issued, another 2-fold in number of shares. we can actually project that share price will eventually drifty towards 0.15p or less. The inverse of exponential is log. The pumping of the shares is becoming more difficult, as more money is needed for incremental rise, Clearly the amount of buys going thru, as some experts pointed out 15m more buys than sells, we can say the Luxembourg is unloading their shares. They have offloaded 60m-70m above 0.40. They had 110m to sell. Once the 40m is sold, they will convert anothef batch possibly this time 150m worth, to keep holding below 30% as the current number of shares in issue is 460 You should expect another 30% dilution this week. Taking the share price around 0.30p Then next one it will be 200m shares most likely a week later.
08/3/2019
17:18
letmepass: : UK Regulatory (RNS & others)TIDMWDCRNS Number : 0841CWideCells Group PLC27 September 201827 September 2018WideCells Group PLC ('WideCells Group' or 'the Group')Financing AgreementWideCells Group PLC, the healthcare services company focused on providing stem cell services and insurance for stem cell treatment, announces it has obtained a flexible and staged GBP2.7 million financing agreement (the 'Agreement') with European High Growth Opportunities Securitization Fund (the 'Investor') represented by its management company, European High Growth Opportunities Manco SA.Terms of the AgreementWideCells Group has entered into an agreement with the Investor in relation to the issue by the Group (the 'Bond Issue') to the Investor (or its affiliates) of convertible bonds (the 'Bonds') with warrants attached for a principal amount of up to GBP2,700,000 (the 'Total Commitment'). Under the terms of the agreement, the Bonds will convert into ordinary shares of GBP0.0025 each in the Company ('Ordinary Shares'), and the warrants entitle ABO to subscribe for Ordinary Shares at a pre-determined price (the 'Warrants').It is expected that the Bonds will be issued and subscribed for in sequential tranches as detailed below:i. GBP635,000 to be subscribed for and paid to the Company immediately; ii. GBP1,000,000 to be subscribed for and paid to the Company immediately on the later of either (a) 15 November 2018, or (b) once a prospectus has been validated and approved by the Financial Conduct Authority (further detail on which is included below);iii. GBP265,000 to be subscribed for and paid to the Company immediately three calendar months after the second tranche if the Company elects to draw down that third tranche; andiv. four subsequent tranches each of aggregate nominal value of GBP200,000 if the Company elects to draw down those tranches.The directors of the Company have sufficient authority to issue shares and rights to subscribe for shares to issue the first tranche of the Bond Issue, but will be required to call a General Meeting to receive authority from shareholders to enable the balance of the Bond Issue, including the attached Warrants, to be implemented. Furthermore, at the current share price, the Bond Issue will result, on full conversion of the Bonds and the attached Warrants, in the issue of substantially more than 20% of the Group's issued share capital triggering a requirement to issue a prospectus (which would need to be approved by the Financial Conduct Authority) prior to the issue of the shares (the 'Prospectus Requirement').The first two drawdowns of the Bonds (totalling GBP1,635,000 in aggregate) are mandatory, but the drawdown of the remainder of the Bonds is not mandatory, although the Investor does have the right to require the Company to draw down any two of the remaining tranches. The Bonds are to be freely transferable and have a maturity of 12 months, after which all the Bonds will be mandatorily converted into Ordinary Shares to the extent not previously converted. The conversion price for the Bonds will be 90% of the lowest closing volume-weighted average price of Ordinary Shares ('VWAP') in the 15 trading days prior to conversion.In relation to the Warrants, all Warrants are exercisable for a period of five years from their date of issue and are to be freely transferable. There are to be two series of Warrants (i.e. Warrants A and Warrants B). The number of Warrants A to be issued on the drawdown of the second tranche would be equivalent to 15% of the Total Commitment divided by the exercise price of the Warrants A. The number of Warrants B to be issued on the drawdown of each tranche will be equivalent to 20% of the nominal value of the Bonds issued in such tranche divided by the exercise price of the Warrants B , although the Warrants B to be issued in respect of the first tranche will actually be issued on the drawdown of the second tranche.The exercise price of the Warrants A will be 120% of the lower of:-- the lowest closing VWAP of the 15 trading days immediately preceding the date of signing of the letter of intent signed by the Company and Alpha Blue Ocean Inc., ('ABO') on 13 September 2018 in relation to the Bond Issue (the 'LOI'); and-- the lowest closing VWAP of the 15 trading days immediately preceding the request to issue the first tranche.The exercise price of the Warrants B will be 120% of the lowest closing VWAP of the 15 trading days immediately preceding the request to issue the relevant tranche (or, in respect of the first tranche only, the lowest closing VWAP of the 15 trading days immediately preceding the date of signing of the LOI in relation to the Bond Issue, if such figure is lower).Use of proceedsProceeds from the Agreement will be used to support the roll out and growth of the Group's stem cell storage and processing (WideCells) and insurance (CellPlan) service offerings and for general working capital purposes. The Board's primary focus is on building the sales revenue of its two core stem cell service offerings by maximising current contract agreements.Within the storage and processing division (WideCells), the Group's offering is a package known as BabyCells, which comprises umbilical cord blood and umbilical cord tissue collection following the award of an HTA license and processing together with one year's storage. The Group launched this product in February 2018 and is now focussed on driving sales uptake within the UK and Europe. This strategy has been strengthened by a recent agreement with an experienced stem cell sales specialist in the UAE and Lebanon.Alongside this, the Group's innovative stem cell insurance division is focussed on increasing the roll-out of CellPlan in a selection of targeted countries in which it currently has commercial agreements in place to facilitate product uptake: namely, the UK and Spain, in both of which it is currently operational, and Brazil, Thailand, India and Singapore, where product launch is targeted to commence on a phased basis in H1 2019.WideCells' CEO, João Andrade, said, "This agreement with ABO provides WideCells Group with financial security so that we can move forward positively and centre our attention on our primary goal and responsibility of building revenues and long-term shareholder value. With a supported balance sheet, we are able to focus on the uptake and sales of our primary stem cell insurance and storage services, which we believe provide the business with strong growth prospects. We have a number of commercial agreements in place to facilitate this and are committed to delivering on our focussed sales strategy for the benefit of all stakeholders."ABO's COO, Hugo Pingray, said "ABO is very pleased to enter into this financing agreement with WideCells which fits ideally into our portfolio. We believe that the Company has the potential to revolutionise the booming stem cell industry and ultimately, to make access to potentially lifesaving treatments much more affordable. We are confident that the management will effectively leverage the funds we provide, to create value for its shareholders in further consolidating and developing its current pipeline.
Widecells share price data is direct from the London Stock Exchange
Your Recent History
LSE
WDC
Widecells
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190717 08:56:32